Panelists discuss how the evolving treatment landscape for metastatic castration-resistant prostate cancer (mCRPC) encompasses multiple therapeutic options including novel hormonal agents, ...

Experts discuss the standard of care and the use of intravesical chemotherapy in the treatment of non–muscle-invasive bladder cancer (NMIBC).

Panelists discuss how radiopharmaceuticals like lutetium-177 prostate-specific membrane antigen (PSMA) may be preferred over systemic therapy in patients with prostate cancer who have high PSMA ...

“In the setting of widespread metastatic progression or failure, we typically prefer more systemic therapy with metastasis-directed therapy for symptomatic sites,” says Kate H. Gessner, MD, PhD. In ...

"I'm always trying new things. I feel like, once you decide that this is the way you have to do it and stick with that forever, that's when you immediately become irrelevant," says Amy E. Krambeck, MD ...

The FDA has accepted the BLA for 89Zr-DFO-girentuximab, granting it priority review for ccRCC imaging. The ZIRCON trial showed high sensitivity (85.5%) and specificity (87%) for the agent in detecting ...

“Having a broader understanding of why someone might be experiencing the disease process or symptoms that they're coming in with is really meaningful and helpful, both to patients and to physicians,” ...

WOLVERINE findings highlight benefits of MDT in oligometastatic prostate cancer ...

Jack Andrews MD; Eugene Cone, MD; and Arash Rezazadeh, MD, discuss how metastatic hormone-sensitive prostate cancer presents clinically, explore current treatment standards including combination ...

“We found that the median rPFS with the combo of mevrometostat plus enzalutamide was 14.3 months, which compared favorably with what we saw with the enzalutamide arm, where the median was only 6.2 ...

Myriad Genetics has licensed PATHOMIQ's AI platform, PATHOMIQ_PRAD, to enhance prostate cancer diagnostics in the US. PATHOMIQ_PRAD predicts biochemical recurrence and metastasis using digitized H&E ...

WOLVERINE findings highlight benefits of MDT in oligometastatic prostate cancer ...